The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

What is the CDDF



The Cancer Drug Development Forum (CDDF) is a non-profit organisation registered in Belgium that provides a neutral platform to stimulate interaction between stakeholders involved in cancer drug development.

The CDDF’s mission is to facilitate collaboration between stakeholders, to increase efficiency in cancer drug development and accelerate the delivery of effective oncology treatment to patients.

Its integrative approach brings together leading voices from academia, the pharmaceutical industry, regulatory authorities, policymakers and patient advocacy groups to improve cancer treatment.



Established in 2001 as the Biotherapy Development Association (BDA), the initial focus of the organisation was immunotherapy. In recognition of the importance of embracing all forms of oncology drug development, the association changed its name to the Cancer Drug Development Forum (CDDF) in 2014.

This new name clearly represents CDDF’s mission to facilitate an exchange of experience from all parties dedicated to developing cancer drugs and delivering effective treatment to patients. The CDDF plays a key role in
identifying silos
and starting dialogue and collaboration, in particular by fully integrating the voice of patients. 

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70